Prediction of benefit from chemotherapy in ER-positive/HER2-negative breast cancer-a problem still to be solved

被引：6

作者：

Schmidt, M. ^{[1
]}

Untch, M. ^{[2
]}

机构：

[1] Univ Hosp, Dept Obstet & Gynaecol, Mainz, Germany

[2] Univ Gottingen, Dept Obstet & Gynaecol, Multidisciplinary Breast Canc Ctr, Helios Klinikum Berlin Buch,Acad Hosp, Berlin, Germany

来源：

ANNALS OF ONCOLOGY | 2014年 / 25卷 / 03期

关键词：

WOMEN;

D O I：

10.1093/annonc/mdt595

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This is a definite statement, however, we want to draw attention to the fact that this evidence is based on two clinical trials including also HER2-positive breast cancer patients. This inclusion of HER2-positive patients might alter the predictive value of RS in luminal HER2-negative breast cancer patients and we thus consider it important to discuss this issue publicly.

引用

页码：754 / 754

页数：1

共 50 条

[1] Reply to: Prediction of benefit from chemotherapy in ER-positive/HER2-negative breast cancer
Goldhirsch, A.
Coates, A. S.
ANNALS OF ONCOLOGY, 2014, 25 (03) : 755 - 755
[2] Estimating the magnitude of clinical benefit of chemotherapy in patients with early ER-positive, HER2-negative breast cancer
McCartney, A.
Di Leo, A.
BREAST, 2019, 44 : S11 - S11
[3] Estimating the magnitude of clinical benefit from (neo)adjuvant chemotherapy in patients with ER-positive/HER2-negative breast cancer
McCartney, Amelia
Benelli, Matteo
Di Leo, Angelo
BREAST, 2019, 48 : S81 - S84
[4] Elacestrant for ER-Positive HER2-Negative Advanced Breast Cancer
Hageman, Elizabeth
Lussier, Mia E.
ANNALS OF PHARMACOTHERAPY, 2024, 58 (08) : 849 - 856
[5] Elacestrant in advanced ER-positive, HER2-negative breast cancer
Lorenz, Judith
GEBURTSHILFE UND FRAUENHEILKUNDE, 2023, 83 (01) : 17 - 17
[6] Challenges in the management of advanced, ER-positive, HER2-negative breast cancer
Christopher D. Hart
Ilenia Migliaccio
Luca Malorni
Cristina Guarducci
Laura Biganzoli
Angelo Di Leo
Nature Reviews Clinical Oncology, 2015, 12 : 541 - 552
[7] Palbociclib and letrozole for ER-positive, HER2-negative advanced breast cancer
Abraham, Jame
Mechcatie, Elizabeth
JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY, 2015, 13 (03): : 83 - 86
[8] Challenges in the management of advanced, ER-positive, HER2-negative breast cancer
Hart, Christopher D.
Migliaccio, Ilenia
Malorni, Luca
Guarducci, Cristina
Biganzoli, Laura
Di Leo, Angelo
NATURE REVIEWS CLINICAL ONCOLOGY, 2015, 12 (09) : 541 - 552
[9] Endocrine therapy for ER-positive/HER2-negative metastatic breast cancer
Reinert, Tomas
de Paula, Bruno
Shafaee, Maryam Nemati
Souza, Pedro Henrique
Ellis, Matthew J.
Bines, Jose
CHINESE CLINICAL ONCOLOGY, 2018, 7 (03)
[10] Endo Predict predicts for the response to neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer
Bertucci, Francois
Finetti, Pascal
Viens, Patrice
Birnbaum, Daniel
CANCER LETTERS, 2014, 355 (01) : 70 - 75

← 1 2 3 4 5 →